Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis

Choy, Ernest Ho Sing, Smith, C. M., Farewell, V., Walker, D., Hassell, A., Chau, L. and Scott, D. L. 2008. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Annals of the Rheumatic Diseases 67 (5) , pp. 656-663. 10.1136/ard.2007.076299

Full text not available from this repository.

Abstract

Objective: Treating early active rheumatoid arthritis (RA) with disease modifying antirheumatic drug (DMARD) monotherapy achieves incomplete outcomes and intensive treatment seems preferable. As the relative benefits of combining two DMARDs, one DMARD with glucocorticoids and two DMARDs with glucocorticoids are uncertain we defined them in a factorial trial. Methods: A 2-year randomised double-blind factorial trial in patients with RA within 2 years of diagnosis treated with methotrexate studied the benefits of added ciclosporin, 9 months intensive prednisolone or both (triple therapy). The primary outcome was the number of patients with new erosions. Secondary outcomes included Larsen’s x-ray scores, disability, quality of life and adverse events. Findings: 1391 patients were screened and 467 randomised. Over 2 years 132 (28%) changed therapy and 88 (19%) were lost to follow-up. The number of patients with new erosions was reduced by nearly half by adding ciclosporin or prednisolone (p = 0.01 and 0.03); both treatments reduced increases in Larsen’s x-ray scores by over 2 units (p = 0.008 and 0.003). A further reduction in erosive damage was seen with combined use of both treatments. Their effects on erosive damage appeared independent. Triple therapy reduced disability and improved quality of life compared with methotrexate; ciclosporin and prednisolone acted synergistically. More patients withdrew because of adverse events with triple therapy, without an increase in serious adverse effects. Conclusions: This study confirms the existence of a “window of opportunity” in early RA, when intensive combination therapy produces sustained benefits on damage and disability. Although methotrexate–prednisolone combinations reduce erosive damage, the synergistic effect of two DMARDs is needed to improve quality of life.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Systems Immunity Research Institute (SIURI)
Subjects: R Medicine > RC Internal medicine
R Medicine > RM Therapeutics. Pharmacology
Publisher: BMJ Publishing Group
ISSN: 0003-4967
Last Modified: 04 Jun 2017 04:21
URI: http://orca.cf.ac.uk/id/eprint/37453

Citation Data

Cited 72 times in Google Scholar. View in Google Scholar

Cited 99 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item